Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes

BACKGROUND: C5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). However, C3-bound PNH red blood cells (RBCs), arising in almost all treated patients, may undergo extravascular hemolysis reducing clinical benefits. Despite the u...

Descripción completa

Detalles Bibliográficos
Autores principales: Sica, Michela, Rondelli, Tommaso, Ricci, Patrizia, De Angioletti, Maria, Risitano, Antonio M., Notaro, Rosario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477256/
https://www.ncbi.nlm.nih.gov/pubmed/28629435
http://dx.doi.org/10.1186/s13045-017-0496-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477256/
https://www.ncbi.nlm.nih.gov/pubmed/28629435
http://dx.doi.org/10.1186/s13045-017-0496-x

Ejemplares similares